These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35461831)

  • 41. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
    Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY.
    Obeid A; Hsu J; Ehmann D; Gao X; Sridhar J; Chiang A; Park CH; Ho AC
    Retin Cases Brief Rep; 2021 Mar; 15(2):120-126. PubMed ID: 29864044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion.
    Chatziralli I; Kazantzis D; Kroupis C; Machairoudia G; Dimitriou E; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Int Ophthalmol; 2022 Nov; 42(11):3449-3457. PubMed ID: 35538256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
    Braimah IZ; Agyabeng K; Amoaku WM
    Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.
    Starr MR; Mahr MA; Iezzi R; Barkmeier AJ; Bakri SJ
    Semin Ophthalmol; 2020 May; 35(4):205-209. PubMed ID: 32721186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
    Tang F; Qin X; Lu J; Song P; Li M; Ma X
    Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion.
    Pidro A; Pidro A; Nadarevic-Vodencarevic A; Halilbasic M; Lepara O; Nisic F
    Rom J Ophthalmol; 2022; 66(1):22-26. PubMed ID: 35531462
    [No Abstract]   [Full Text] [Related]  

  • 51. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
    Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
    Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
    Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
    Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P
    Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
    Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
    Retina; 2005; 25(7):846-50. PubMed ID: 16205562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.
    Spooner K; Hong T; Bahrami B; Chang A
    Acta Ophthalmol; 2019 Feb; 97(1):15-23. PubMed ID: 30251325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial.
    Nourinia R; Emamverdi M; Ramezani A; Amizadeh Y; Khorshidifar M; Behnaz N; Safi S
    Retina; 2020 Jun; 40(6):1110-1117. PubMed ID: 31157710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study.
    O'Day R; Ali N; Lim LL; Sandhu S; Chau T; Wickremasinghe S
    BMC Ophthalmol; 2020 Feb; 20(1):69. PubMed ID: 32093666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.